Filing Flows › Comparisons › OCUL vs ASMB
Ocular Therapeutix vs Assembly Biosciences: OCUL and ASMB compared
Ocular Therapeutix is the larger company: $13.5M of revenue in its latest quarter (Q2 2026) against $13.4M for Assembly Biosciences (Q2 2026). Assembly Biosciences is growing faster (+39% against +0.1% a year earlier). Assembly Biosciences is more profitable, with an operating margin of -47.4% against -609.3%.
Where the money goes: OCUL and ASMB
Ocular Therapeutix (OCUL) · Q2 2026
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
Assembly Biosciences (ASMB) · Q2 2026
Assembly Biosciences, Q2 2026: revenue $13.4M (+39% year over year), operating margin -47.4%, net loss $3.9M, operating cash flow −$15.5M. The chart follows the revenue to costs, profit and cash.
| Ocular Therapeutix (OCUL) | Assembly Biosciences (ASMB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $13.5M | $13.4M |
| Revenue growth, Y/Y | +0.1% | +39% |
| Operating margin | -609.3% | -47.4% |
| Net earnings | −$78.8M | −$3.9M |
| Net margin | -584.5% | -28.8% |
| Operating cash flow | −$67.3M | −$15.5M |
Questions
Which is bigger, Ocular Therapeutix or Assembly Biosciences?
Ocular Therapeutix is the larger company: $13.5M of revenue in its latest quarter (Q2 2026) against $13.4M for Assembly Biosciences (Q2 2026).
Is Ocular Therapeutix or Assembly Biosciences growing faster?
Assembly Biosciences is growing faster (+39% against +0.1% a year earlier).
Which is more profitable, Ocular Therapeutix or Assembly Biosciences?
Assembly Biosciences is more profitable, with an operating margin of -47.4% against -609.3%.
More: Ocular Therapeutix earnings · how Ocular Therapeutix makes money · Assembly Biosciences earnings · how Assembly Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 3, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.